CLAIMS

1. A compound having the formula **Ia** or **Ib**



(Ia)



(Ib)

wherein:

P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one heteroatom is nitrogen;

R^1 is hydrogen;

R^2 is selected from: C_{1-6}alkyl, cyano, halogen, $(CO)OR^{10}$, and $CONR^{10}R^{11}$;

R^3 is selected from: C_{1-6}alkyl, cyano, nitro, $(CO)OR^4$, C_{1-6}alkylNR^4R^5, OC_{2-6}alkylNR^4R^5, $CONR^4R^5$,SO_2R^4, OSO_2R^4 and $(SO_2)NR^4R^5$;

R^4 is selected from: hydrogen, CF_3 and C_{1-6}alkyl;

R^5 is selected from: hydrogen, C_{1-6}alkyl, C_{1-6}alkylNR^6R^7 and; wherein R^4 and R^5 may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R^6 and R^7 are independently selected from hydrogen, C_{1-6}alkyl, $(CO)C_{1-6}$alkyl, and wherein R^6 and R^7 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

R^8 and R^9 are independently selected from: hydrogen and C_{1-6}alkyl and wherein R^8 and R^9 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S;

R^{10} is selected from hydrogen and C_{1-6}alkyl;

R^{11} is selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkylCN, C_{0-6}alkylaryl, C_{2-6}alkylOR^8, C_{1-6}alkyl$(CO)NR^6R^7$, C_{1-6}alkyl$(SO_2)R^6$, C_{1-6}alkyl$(SO_2)NR^6R^7$, C_{0-6}alkylheteroaryl, C_{0-6}alkylC_{3-6}heterocyclic group and C_{1-6}alkylNR^6R^7; and wherein any C_{0-6}alkylaryl and C_{0-6}alkylheteroaryl may be substituted by one or more group Z; and wherein any C_{0-6}alkylC_{3-6}heterocyclic group may be substituted by one or more group Y;

Z is selected from halo, C_{1-6}alkyl, C_{1-6}alkoxy, OCF_3 and CF_3;

Y is selected from: oxo, C_{2-6}alkylOR^8, C_{1-6}alkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, OR^8 and C_{2-6}alkylNR^8R^9;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, 3 or 4;

as a free base or a salt, or a tautomer thereof.

2. A compound according to claim 1, wherein;

P represents a 6-membered heteroaromatic ring containing one heteroatom selected independently from N and O;

R^2 is selected from: cyano, halogen, $(CO)OR^{10}$, and $CONR^{10}R^{11}$;

R^3 is selected from: cyano, nitro, $C_{1-6}alkylNR^4R^5$, $OC_{2-6}alkylNR^4R^5$, $CONR^4R^5$, and $(SO_2)NR^4R^5$;

R^4 is selected from: hydrogen and $C_{1-6}alkyl$;

R^5 is selected from: $C_{1-6}alkyl$ and $C_{1-6}alkylNR^6R^7$ and; wherein R^4 and R^5 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R^6 and R^7 are independently selected from hydrogen, $(CO)C_{1-6}alkyl$, and wherein R^6 and R^7 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

R^8 and R^9 are independently selected from: hydrogen and $C_{1-6}alkyl$ and wherein R^8 and R^9 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N and O;

R^{10} is selected from hydrogen and $C_{1-6}alkyl$;

R^{11} is selected from hydrogen, $C_{1-6}alkyl$, $C_{1-6}alkylCN$, $C_{0-6}alkylaryl$, $C_{2-6}alkylOR^8$, $C_{1-6}alkyl(CO)NR^6R^7$, $C_{1-6}alkyl(SO_2)R^6$, $C_{1-6}alkyl(SO_2)NR^6R^7$, $C_{0-6}alkylheteroaryl$, $C_{0-6}alkylC_{3-6}heterocyclic$ group and $C_{1-6}alkylNR^6R^7$; and wherein any $C_{0-6}alkylaryl$ may be substituted by one or more group Z;

Z is selected from halo, $C_{1-6}alkoxy$, OCF_3 and CF_3;

Y is selected from: oxo, $C_{2-6}alkylOR^8$, $C_{1-6}alkyl$ and $C_{2-6}alkylNR^8R^9$;

m is 1 or 2;

n is 1.

3. A compound according to claim 1 or 2, wherein P is pyridine.

4. A compound according to any one of claims 1 to 3, wherein R^2 is selected from cyano, $(CO)OR^{10}$, and $CONR^{10}R^{11}$.

5. A compound according to claim 1, wherein R^2 is $CONR^{10}R^{11}$ and R^{11} is selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkylCN, C_{2-6}alkylOR^8, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl; and wherein any C_{0-6}alkylaryl and C_{0-6}alkylheteroaryl may be substituted by one or more group Z and wherein Z is selected from C_{1-6}alkoxy, OCF_3 and CF_3.

6. A compound according to any one of claims 1 to 5, wherein R^3 is selected from: C_{1-6}alkylNR^4R^5, OC_{2-6}alkylNR^4R^5, $CONR^4R^5$, and $(SO_2)NR^4R^5$; and wherein R^4 and R^5 may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y, and wherein Y may be C_{1-6}alkyl.

7. A compound according to any one of claims 1 to 5, wherein R^3 is selected from: C_{1-6}alkylNR^4R^5, OC_{2-6}alkylNR^4R^5, $CONR^4R^5$, and $(SO_2)NR^4R^5$; and R^5 is C_{1-6}alkylNR^6R^7 and wherein R^6 and R^7 may together form a 5- or 6-membered heterocyclic group containing one or two heteroatoms, selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y.

8. A compound according to any one of claims 1 to 5, wherein R^3 is C_{1-6}alkylNR^4R^5 and wherein R^4 and R^5 may together form a 6-membered heterocyclic group containing one or two heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y and wherein Y may be C_{1-6}alkyl or oxo.

9. A compound which is

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylnicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;

2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

3-[5-({4-[2-(Dipropylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-morpholin-4-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-(5-{[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(3-methoxypropyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride:

2-Hydroxy-*N*-(2-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-3-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-4-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(methylsulfonyl)ethyl]-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-{2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-sulfonamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carboxamide hydrochloride;

3-[5-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-methyl-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-isopropyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-pyrrolidin-1-ylethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-[3-(Dimethylamino)propyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-pyridin-3-yl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(3-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-*N*-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfon]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Furylmethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-6-carbonitrile hydrochloride;

3-{6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl}-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-thienyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid carbamoylmethylamide hydrochloride;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(methylsulfonyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;
Methyl 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-5-carboxylate hydrochloride;
3-(5-Diethylaminomethyl-pyridin-2-yl)-2-hydroxy-1H-indole-5-carboxylic acid (2-methanesulfonyl-ethyl)-amide hydrochloride;

as a free base or another salt than hydrochloride, or a tautomer thereof;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-(4-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide;
2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid (2-carbamoylethyl)amide;
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid methyl ester;
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid (thiophen-2-ylmethyl)-amide dihydrochloride;
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid benzylamide dihydrochloride;

as a free base or a salt, or a tautomer thereof.

10. A compound according to claim 9, which is in the form of a pharmaceutically acceptable salt.

11. A compound which is

6-Chloronicotinic acid 1-oxide;
Ethyl 6-chloronicotinate 1-oxide;
1-[(6-Chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine;

tert-Butyl 4-[(6-chloropyridin-3-yl)sulfonyl]piperazine-1-carboxylate ;
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dipropylamine;
4-(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)morpholine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-pyrrolidin-1-ylethyl)piperazine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(2-methoxyethyl)piperazine;
6-Chloro-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
(2-{4-[(6-Chloropyridin-3-yl)sulfonyl]piperazin-1-yl}ethyl)dimethylamine;
2-Oxo-*N*-(pyridin-2-ylmethyl)indoline-5-carboxamide;
2-Oxo-*N*-(2-thienylmethyl)indoline-5-carboxamide;
2-Oxo-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]indoline-5-carboxamide;
N-[2-(Acetylamino)ethyl]-2-oxoindoline-5-carboxamide;
N-(3-Methoxypropyl)-2-oxoindoline-5-carboxamide;
6-Bromo-*N*-isopropyl-2-oxoindoline-5-carboxamide;
6-Bromo-*N*-(2-methoxyethyl)-2-oxoindoline-5-carboxamide;
6-Bromo-2-oxo-*N*-(tetrahydrofuran-2-ylmethyl)indoline-5-carboxamide;
6-Bromo-2-oxo-*N*-(2-pyrrolidin-1-ylethyl)indoline-5-carboxamide;
N-[3-(Dimethylamino)propyl]-2-oxoindoline-5-carboxamide;
N-(2-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
N-(3-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
N-(4-Methoxybenzyl)-2-oxoindoline-5-carboxamide;
2-Oxo-*N*-(tetrahydro-2*H*-pyran-4-yl)indoline-5-carboxamide;
N-Benzyl-2-oxoindoline-5-carboxamide;
N-(2-Methoxyethyl)-2-oxoindoline-5-carboxamide;
2-Oxo-*N*-propylindoline-5-carboxamide;
N-[2-(Dimethylamino)ethyl]-2-oxoindoline-5-carboxamide;
N-(2-Cyanoethyl)-2-oxoindoline-5-carboxamide;
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]morpholine;
4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine;
N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-*N*-ethylethanamine;
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methylpiperazine;
1-[(6-chloro-1-oxidopyridine-3-yl)methyl]piperidine;
4-[(6-Chloro-1-oxidopyridin-3-yl)methyl]piperazin-2-one;

N-{2-[(4-Methylpiperazin-1-yl)sulfonyl]ethyl}-2-oxoindoline-5-carboxamide;
4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;
N-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}-*N*-isopropylpropan-2-amine;
Ethyl 6-(6-cyano-2-hydroxy-1*H*-indol-3-yl)nicotinate;
Methyl 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxylate;
Methyl 3-{5-[(diethylamino)methyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carboxylate;
Methyl 2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylate;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid;
Methyl 3-(4-cyanopyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylate;
as a free base or a salt, or a tautomer thereof.

12. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 10 in association with pharmaceutically acceptable carriers or diluents.

13. The pharmaceutical formulation according to claim 12 for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

14. A compound as defined in any one of claims 1 to 10 for use in therapy.

15. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

16. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologie and dementia pugilistica.

17. The use according to claim 16 wherein the prevention and/or treatment is for Alzheimer's Disease.

18. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication and Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

19. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

20. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for prevention and/or treatment of bone-related disorders.

21. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administrering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.

22. A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administrering to a mammal, including

man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.

23. The method according to claim 22, wherein the prevention and/or treatment is for Alzheimer's Disease.

24. A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders,comprising administrering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.

25. A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administrering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.

26. A method of prevention and/or treatment of bone-related disorders, comprising administrering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 to 10.

27. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein P, R^1, R^2 and R^3, m and n, unless otherwise specified, are defined in claim 1,

comprising reacting a compound of formula **A**, wherein L^1 is a leaving group, with a compound of formula **D** to form a compound of formula **Ia**;



(A) **(D)** **(Ia)**

said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

28. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^1, R^2 and R^3 and m, is as defined in claim 1, and halo is halogen, unless otherwise specified, comprising reacting a compound of formula **B** with a compound of formula **D** to form a compound of formula **Ia**;



(B) **(D)** **(Ia)**

said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

29. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^3 is $CONR^4R^5$, comprising reacting a compound of formula **XIX**, wherein R^4 is C_{1-6}alkyl, with the appropriate amine HNR^4R^5, to form a compound of formula **Ia**;



(XIX) **(Ia)**

said reaction being carried out by;

i) reacting the compound of formula **XIX** with the appropriate amine R^4R^5NH in a suitable solvent in the presence of a suitable reagent at a reaction temperature between 0 °C and reflux or;

ii) reacting the compound of formula **XIX** with the appropriate amine R^4R^5NH neat or in a suitable solvent with or without a suitable base or an alkylamine base at a temperature between -20 °C and +150 °C.

30. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^2 is $CONR^{10}R^{11}$, comprising amidation of a compound of formula **C**, wherein R^4 is C_{1-6}alkyl, to form a compound of the formula **Ia**;



(C) (Ia)

said reaction being carried out with the appropriate amine $HNR^{10}R^{11}$ in a suitable solvent in the presence of trimethylaluminum and at a reaction temperature between –10 °C and reflux.

31. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^2 is $CONR^{10}R^{11}$, comprising amidation of a compound of formula **E**, to form a compound of the formula **Ia**, with the appropriate amine $HNR^{10}R^{11}$;



(E) (Ia)

carried out by activation of the acid function in a compound of formula **E** with;

a) a halogenation reagent in a suitable solvent at a temperature between 0 °C and +80 °C, followed by the reaction with the appropriate amine $HNR^{10}R^{11}$ in a suitable solvent with or without a suitable base at a temperature between -20 °C and +80 °C, or;

b) a coupling reagent where the reaction is carried out in a suitable solvent at a temperature between +20 °C and +130 °C, followed by addition of the appropriate amine $HNR^{10}R^{11}$.

32. A process for the preparation of a compound of formula **Ia** according to claim 1, wherein R^3 is $C_{1-6}alkylNR^4R^5$, comprising fluorinating a compound of formula **XXIa** to form a compound of formula **Ib**.



(XXIa) (Ib)

said reaction being carried out in an appropriate solvent in the presence of a suitable fluorinating reagent and a suitable base at a reaction temperature between -40 °C and +80 °C.

33. The use of the intermediates according to claim 11 for the preparation of a compound of formula **Ia** or **Ib** as defined in any one of claims 1 to 10.